AIM Stock Overview An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
AIM ImmunoTech Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for AIM ImmunoTech Historical stock prices Current Share Price US$0.21 52 Week High US$0.62 52 Week Low US$0.16 Beta -0.40 1 Month Change -8.64% 3 Month Change -25.61% 1 Year Change -52.65% 3 Year Change -77.36% 5 Year Change -62.80% Change since IPO -99.99%
Recent News & Updates
Less than half of directors are independent Dec 26 AIM ImmunoTech Receives Non-Compliance Letter from NYSE American
Ted Kellner Provides Information to the Shareholders Dec 17
Consensus EPS estimates upgraded to US$0.30 loss Dec 11
Ted D. Kellner Files Definitive Proxy Statement with Securities and Exchange Commission Dec 11
AIM Immunotech Inc. Appoints William A. Carter as Chairman of Scientific Advisory Board Dec 10 See more updates
Less than half of directors are independent Dec 26 AIM ImmunoTech Receives Non-Compliance Letter from NYSE American
Ted Kellner Provides Information to the Shareholders Dec 17
Consensus EPS estimates upgraded to US$0.30 loss Dec 11
Ted D. Kellner Files Definitive Proxy Statement with Securities and Exchange Commission Dec 11
AIM Immunotech Inc. Appoints William A. Carter as Chairman of Scientific Advisory Board Dec 10
Kellner Group Issues Press Release to Urge AIM Immunotech Stockholders to Vote the Gold Card Dec 03
New major risk - Revenue and earnings growth Nov 24
New major risk - Financial position Nov 17
Kellner Group Urges Immediate Change at AIM Immunotech Inc Nov 15
AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024 Nov 06 AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024 Nov 05
Price target increased by 19% to US$4.25 Oct 24 AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million. Oct 02
AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million. Sep 30
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Sep 19
Ted D. Kellner Sends a Notice to AIM ImmunoTech Sep 04
Consensus EPS estimates fall by 15% Sep 03
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Aug 20
Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023) Aug 16
Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board Aug 15
AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy Jul 24
AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million. Jun 02 AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million. Jun 01
Consensus revenue estimates increase by 52% May 26
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023) May 17
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Apr 10
New minor risk - Shareholder dilution Apr 08
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024 Mar 27
Price target decreased by 30% to US$2.75 Mar 15 AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding Feb 21
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Feb 08
AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023 Nov 29
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions Nov 22
Consensus EPS estimates fall by 12% Nov 21
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 17
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen Nov 15
AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer Nov 09
AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023 Nov 08
AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023 Nov 07
Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation Aug 29
Consensus revenue estimates increase by 15% Aug 21
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 16
AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions Aug 09
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions Jul 12
AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer Jun 28
AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments Jun 13
Price target decreased by 7.8% to US$4.92 May 24
Price target decreased by 7.7% to US$5.00 May 19
First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022) May 16
Consensus revenue estimates decrease by 83%, EPS upgraded Apr 06
AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod) Jan 10
Executive Vice Chairman recently bought US$50k worth of stock Jan 05
AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer Dec 13
Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects Dec 10
Consensus revenue estimates fall by 34% Nov 21
Insufficient new directors Nov 16
AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen Nov 15
ASFV Committee Issues a Statement on Ruling in Delaware Action Nov 02
ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action Oct 25
Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech Oct 20
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Oct 14
AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions Oct 13
Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech Sep 30
AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022 Sep 21
AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022 Sep 20 AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma
Consensus revenue estimates fall by 23% Aug 22
AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer Aug 19
Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation Aug 17
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 16
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID Jul 29
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc Jul 23
Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc Jul 22
AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data Jul 21
Consensus forecasts updated May 20
AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program May 19
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 14
Price target increased to US$7.25 Apr 27
Insufficient new directors Apr 27
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies Apr 22 Shareholder Returns AIM US Biotechs US Market 7D 9.6% 0.7% 0.6% 1Y -52.6% -3.4% 23.8%
See full shareholder returns
Return vs Industry: AIM underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: AIM underperformed the US Market which returned 24.6% over the past year.
Price Volatility Is AIM's price volatile compared to industry and market? AIM volatility AIM Average Weekly Movement 10.3% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: AIM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AIM's weekly volatility (10%) has been stable over the past year.
About the Company AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
Show more AIM ImmunoTech Inc. Fundamentals Summary How do AIM ImmunoTech's earnings and revenue compare to its market cap? AIM fundamental statistics Market cap US$12.82m Earnings (TTM ) -US$23.93m Revenue (TTM ) US$190.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AIM income statement (TTM ) Revenue US$190.00k Cost of Revenue US$36.00k Gross Profit US$154.00k Other Expenses US$24.08m Earnings -US$23.93m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.38 Gross Margin 81.05% Net Profit Margin -12,594.21% Debt/Equity Ratio 93.8%
How did AIM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 05:25 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources AIM ImmunoTech Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Ling Wang Chardan Capital Markets, LLC Jason McCarthy Maxim Group
Show 1 more analysts 
